<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of rapidly progressing or progressively disfiguring cutaneous sarcoidosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of rapidly progressing or progressively disfiguring cutaneous sarcoidosis</h1>
<div class="graphic"><div class="figure"><div class="ttl">Treatment of rapidly progressing or progressively disfiguring cutaneous sarcoidosis</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">The approach to the treatment of less severe cutaneous sarcoidosis is reviewed in the UpToDate topic on the management of cutaneous sarcoidosis.</div><div class="graphic_footnotes">HCQ: hydroxychloroquine; MTX: methotrexate.<br/>* The onset of action of these drugs is often delayed. We often continue prednisone early in the course of therapy until clinical improvement. Prednisone is subsequently tapered as tolerated. Similarly, HCQ or MTX are frequently continued while awaiting a response. The best course for patients who fail these agents is unclear. A variety of other therapies have been utilized for refractory cutaneous sarcoidosis, but efficacy data are limited. Refer to UpToDate topics on the management of cutaneous sarcoidosis for details on the use of these therapies and additional treatment options.</div><div id="graphicVersion">Graphic 120775 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
